SPRBSpruce Biosciences Inc
$49.32
$1.11
(2.20%)
Closed $49.32
$4.01
(8.13%)
After Hours
Mkt Cap$138.8M
Vol31,277.00
Fundamentals
Mkt Cap
$138.8M
Volume
-
52W High
$240.00
52W Low
$4.35
PE Ratio
-1.31
Avg. Volume
47,047.72
EPS (Annual)
-$50.83
Rev/Employee
$0.00
Earnings
-
61
Bullish Sentiment
How do you feel about SPRB?
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data demonstrating the long-term benefit of tralesinidase alfa enzyme...
Business Wire
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme...
Business Wire
Spruce Biosciences to Participate in Upcoming Conferences in June
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that members of the management team will present and participate in one-on-one...
Business Wire
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...
Business Wire
Spruce Biosciences (SPRB) Projected to Post Earnings on Tuesday
Spruce Biosciences (NASDAQ:SPRB) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...
MarketBeat
Craig Hallum Initiates Coverage on Spruce Biosciences (NASDAQ:SPRB)
Craig Hallum initiated coverage on Spruce Biosciences in a report on Monday. They set a "buy" rating and a $140.00 price target on the stock...
MarketBeat
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Recommendation of "Hold" from Brokerages
Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) have been given a consensus recommendation of "Hold" by the seven brokerages that are covering the company, Marketbeat reports. One...
MarketBeat
Why Is Spruce Biosciences Stock Sinking Tuesday?
Spruce Biosciences (SPRB) shares drop 21% in premarket trading following a $60 million public stock offering priced at $50 per share.read more...
Benzinga
Spruce Biosciences Prices Public Offering To Fund Neuro Therapies
(RTTNews) - Spruce Biosciences Inc. (SPRB) announced that it has priced a public offering expected to raise $60 million in gross proceeds to advance its neurological disorder therapies...
Nasdaq News: Markets
<
1
2
...
>
Advertisement|Remove ads.
Latest SPRB News
ViewSpruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
Business Wire
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
Business Wire
Spruce Biosciences to Participate in Upcoming Conferences in June
Business Wire
Advertisement|Remove ads.